There has been much coverage in the national and international press that Novo Nordisk has recently been suspended from membership of the ABPI, the representative trade association for the pharmaceutical industry in the UK. This is in response to inappropriate activities surrounding their weight loss product, Saxenda (not Wegovy, although questions are now being asked as to the approval processes that were followed with Wegovy, and the transparency of the relationship between expert advisors engaged additionally by Novo Nordisk).
Pharma Integrity has provided a summary of the circumstances surrounding the case that triggered this suspension, albeit it needs to be considered that there were additional issues with Novo Nordisk activities considered by the PMCPA (including audit) in the past couple of years; their suspension does not solely reflect the findings of this case in isolation.